Michael T. Dill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael T. Dill has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Markus Hermann Heim
Department of Biomedicine, University of Basel, Basel, Switzerland
18 shared publications Luigi Terracciano
Institute of Pathology, University Hospital of Basel Basel Switzerland
9 shared publicationsZuzanna Makowska
Hepatology Laboratory, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland
9 shared publications- Luigi Tornillo
Institute of Pathology
6 shared publications - Fernando D. Camargo
Stem Cell Program, Boston Children's Hospital, Boston, MA, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA
5 shared publications - Francois H. T. Duong
Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
5 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab
Background/Aims: Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin‐6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin‐6 and developed a combined score (ALBI‐6) integrating interleukin‐6 with albumin–bilirubin grade, a marker of liver function. Methods: In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first‐line atezolizumab plus bevacizumab were analysed. Interleukin‐6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set ( n = 98) and a validation set ( n = 90). ALBI‐6 was derived using Cox regression and evaluated against several established prognostic scores. Results: Elevated baseline interleukin‐6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha‐fetoprotein, performance status, liver function class). In the validation cohort, ALBI‐6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log‐rank p = 0.002); ALBI‐6 was significantly more discriminative than one comparator score (modified albumin–bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI‐6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability. Conclusions: ALBI‐6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.
- 8 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab
Background/Aims: Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin‐6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin‐6 and developed a combined score (ALBI‐6) integrating interleukin‐6 with albumin–bilirubin grade, a marker of liver function. Methods: In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first‐line atezolizumab plus bevacizumab were analysed. Interleukin‐6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set ( n = 98) and a validation set ( n = 90). ALBI‐6 was derived using Cox regression and evaluated against several established prognostic scores. Results: Elevated baseline interleukin‐6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha‐fetoprotein, performance status, liver function class). In the validation cohort, ALBI‐6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log‐rank p = 0.002); ALBI‐6 was significantly more discriminative than one comparator score (modified albumin–bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI‐6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability. Conclusions: ALBI‐6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.
- Open Access
UELer: a Jupyter-based framework for interactive exploration of multiplexed imaging datasets
Summary Multiplexed imaging and spatial proteomics generate complex datasets that require both computational analysis and visual inspection. However, these tasks mostly occur in separate environments because interactive viewers generally require a local display or an additional data server beyond the remote Jupyter sessions itself where large datasets are computationally analyzed. We here present UELer, an interactive viewer that links multi-channel image views with quantitative analysis results directly within Jupyter notebooks, requiring no dedicated infrastructure beyond the notebook session. Cells selected through computational analysis and summary plots can be inspected directly in their tissue context, and selections made in the image can be made available to any downstream analysis. Together, these capabilities support interactive data exploration, iterative cell annotation, and reproducible retrieval of selected regions. Availability and Implementation UELer is a Python package built on ipywidgets and runs in Jupyter environments supporting ipywidgets 8.1 or later, tested in JupyterLab and Visual Studio Code on Linux, macOS, and Windows. It is freely available under GPL-3.0 license and can be installed via pip. Source code and documentation are available at https://github.com/HartmannLab/UELer and https://hartmannlab.github.io/UELer/. An online, no-install version runs remotely via BinderHub (https://mybinder.org/v2/gh/HartmannLab/UELer/main), accessible through the script/run_ueler_binder.ipynb notebook.
Open AccessUELer: a Jupyter-based framework for interactive exploration of multiplexed imaging datasets
Summary Multiplexed imaging and spatial proteomics generate complex datasets that require both computational analysis and visual inspection. However, these tasks mostly occur in separate environments because interactive viewers generally require a local display or an additional data server beyond the remote Jupyter sessions itself where large datasets are computationally analyzed. We here present UELer, an interactive viewer that links multi-channel image views with quantitative analysis results directly within Jupyter notebooks, requiring no dedicated infrastructure beyond the notebook session. Cells selected through computational analysis and summary plots can be inspected directly in their tissue context, and selections made in the image can be made available to any downstream analysis. Together, these capabilities support interactive data exploration, iterative cell annotation, and reproducible retrieval of selected regions. Availability and Implementation UELer is a Python package built on ipywidgets and runs in Jupyter environments supporting ipywidgets 8.1 or later, tested in JupyterLab and Visual Studio Code on Linux, macOS, and Windows. It is freely available under GPL-3.0 license and can be installed via pip. Source code and documentation are available at https://github.com/HartmannLab/UELer and https://hartmannlab.github.io/UELer/. An online, no-install version runs remotely via BinderHub (https://mybinder.org/v2/gh/HartmannLab/UELer/main), accessible through the script/run_ueler_binder.ipynb notebook.
- Open Access
- 21 July 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (10)
FGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine model
- 21 July 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (10)
Open AccessFGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine model
- Open Access
- 17 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (2) , 227-237
Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis
- 17 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (2) , 227-237
Open AccessVitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis
- Open Access
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eaeb2333
Hepatitis E virus replication is maintained in proliferative cells within the intestinal crypt
The hepatitis E virus (HEV) is a leading cause of acute hepatitis worldwide. Although most infections are self-limiting, zoonotic genotypes can persist in immunocompromised individuals. Transmitted via the fecal-oral route, HEV has been suggested to directly infect the intestinal epithelium, a tissue with high regenerative capacity. Here, we demonstrate that HEV predominantly infects proliferative transit-amplifying and intestinal stem cells within the crypts of human pluripotent stem cell–derived intestinal organoids (hIOs). Supporting this, we detected HEV RNA in the intestinal crypts of an HEV-infected patient. We further found that HEV infection spreads through cell division and is maintained in hIOs for more than 40 days, contrasting with acute hepatitis A virus, whose infections are rapidly cleared from hIOs. Given the self-renewal ability and metabolic constraints of proliferative intestinal progenitor cells, our findings suggest that intestinal crypts could serve as reservoirs for chronic HEV infection and highlight the intestinal crypt as a primary target for viral infection in the gastrointestinal tract.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eaeb2333
Open AccessHepatitis E virus replication is maintained in proliferative cells within the intestinal crypt
The hepatitis E virus (HEV) is a leading cause of acute hepatitis worldwide. Although most infections are self-limiting, zoonotic genotypes can persist in immunocompromised individuals. Transmitted via the fecal-oral route, HEV has been suggested to directly infect the intestinal epithelium, a tissue with high regenerative capacity. Here, we demonstrate that HEV predominantly infects proliferative transit-amplifying and intestinal stem cells within the crypts of human pluripotent stem cell–derived intestinal organoids (hIOs). Supporting this, we detected HEV RNA in the intestinal crypts of an HEV-infected patient. We further found that HEV infection spreads through cell division and is maintained in hIOs for more than 40 days, contrasting with acute hepatitis A virus, whose infections are rapidly cleared from hIOs. Given the self-renewal ability and metabolic constraints of proliferative intestinal progenitor cells, our findings suggest that intestinal crypts could serve as reservoirs for chronic HEV infection and highlight the intestinal crypt as a primary target for viral infection in the gastrointestinal tract.
- Open Access
Cell-of-Origin, not Oncogenic Effect, Determines Desmoplastic Immune Exclusion in KRAS-Driven Liver Cancer
Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the two most common primary liver cancers and share common risk factors. Yet they exhibit distinct oncogenic driver landscapes and fundamentally different tumor microenvironments (TME), with iCCA characterised by dense desmoplastic stroma that limits therapeutic efficacy. Whether these differences reflect oncogenic context or the developmental lineage of the cancer cell has remained unresolved. Here, using syngeneic orthotopic murine models derived from CRISPR-engineered cholangiocyte and hepatocyte organoids each carrying Trp53 deletion and Kras G12D mutation, we show that cell-of-origin, not oncogenic pathway activation, is the dominant determinant of TME architecture. Spatial proteomics of ∼390,000 cells reveals that cholangiocyte-derived tumors develop a stromal barrier of peripherally enriched αSMA + cancer-associated fibroblasts (CAFs) that physically excludes immune cells and elevates PD-1/PD-L1 engagement, whereas hepatocyte derived tumors permit broader immune infiltration. Transcriptional variance partitioning confirms lineage as the primary source of gene expression divergence. Integrating murine and human transcriptomic and secretomic datasets, we identify LAMC2 and uPA as cholangiocyte lineage-specific secreted factors that trigger CAF activation. Genetic deletion of either factor markedly impairs iCCA formation in vivo . These findings establish that lineage-encoded secretory programmes create a desmoplastic and immune-excluded stroma and identify LAMC2 and uPA as functionally relevant modulators of TME in KRAS-driven iCCA.
Open AccessCell-of-Origin, not Oncogenic Effect, Determines Desmoplastic Immune Exclusion in KRAS-Driven Liver Cancer
Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the two most common primary liver cancers and share common risk factors. Yet they exhibit distinct oncogenic driver landscapes and fundamentally different tumor microenvironments (TME), with iCCA characterised by dense desmoplastic stroma that limits therapeutic efficacy. Whether these differences reflect oncogenic context or the developmental lineage of the cancer cell has remained unresolved. Here, using syngeneic orthotopic murine models derived from CRISPR-engineered cholangiocyte and hepatocyte organoids each carrying Trp53 deletion and Kras G12D mutation, we show that cell-of-origin, not oncogenic pathway activation, is the dominant determinant of TME architecture. Spatial proteomics of ∼390,000 cells reveals that cholangiocyte-derived tumors develop a stromal barrier of peripherally enriched αSMA + cancer-associated fibroblasts (CAFs) that physically excludes immune cells and elevates PD-1/PD-L1 engagement, whereas hepatocyte derived tumors permit broader immune infiltration. Transcriptional variance partitioning confirms lineage as the primary source of gene expression divergence. Integrating murine and human transcriptomic and secretomic datasets, we identify LAMC2 and uPA as cholangiocyte lineage-specific secreted factors that trigger CAF activation. Genetic deletion of either factor markedly impairs iCCA formation in vivo . These findings establish that lineage-encoded secretory programmes create a desmoplastic and immune-excluded stroma and identify LAMC2 and uPA as functionally relevant modulators of TME in KRAS-driven iCCA.
- Open Access
- 5 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study
- 5 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Open AccessClinical practice and implications of biomarker testing in biliary tract cancer: An observational study
- Open Access
- 19 August 2025
- Published by Springer Nature in Cancer Imaging
- Vol. 25 (1) , 1-13
Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE
Background: Accurate prediction of tumor response after drug-eluting beads transarterial chemoembolization (DEB-TACE) remains challenging in hepatocellular carcinoma (HCC), given tumor heterogeneity and dynamic changes over time. Existing prediction models based on single timepoint imaging do not capture dynamic treatment-induced changes. This study aims to develop and validate a predictive model that integrates deep learning and machine learning algorithms on longitudinal contrast-enhanced MRI (CE-MRI) to predict treatment response in HCC patients undergoing DEB-TACE. Methods: This retrospective study included 202 HCC patients treated with DEB-TACE from 2004 to 2023, divided into a training cohort ( n = 141) and validation cohort ( n = 61). Radiomics and deep learning features were extracted from standardized longitudinal CE-MRI to capture dynamic tumor changes. Feature selection involved correlation analysis, minimum redundancy maximum relevance, and least absolute shrinkage and selection operator regression. The patients were categorized into two groups: the objective response group ( n = 123, 60.9%; complete response = 35, 28.5%; partial response = 88, 71.5%) and the non-response group ( n = 79, 39.1%; stable disease = 62, 78.5%; progressive disease = 17, 21.5%). Predictive models were constructed using radiomics, deep learning, and integrated features. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of the models. Results: We retrospectively evaluated 202 patients (62.67 ± 9.25 years old) with HCC treated after DEB-TACE. A total of 7,182 radiomics features and 4,096 deep learning features were extracted from the longitudinal CE-MRI images. The integrated model was developed using 13 quantitative radiomics features and 4 deep learning features and demonstrated acceptable and robust performance with an receiver operating characteristic curve (AUC) of 0.941 (95%CI: 0.893–0.989) in the training cohort, and AUC of 0.925 (95%CI: 0.850–0.998) with accuracy of 86.9%, sensitivity of 83.7%, as well as specificity of 94.4% in the validation set. Conclusions: This study presents a predictive model based on longitudinal CE-MRI data to estimate tumor response to DEB-TACE in HCC patients. By capturing tumor dynamics and integrating radiomics features with deep learning features, the model has the potential to guide individualized treatment strategies and inform clinical decision-making regarding patient management.
- 19 August 2025
- Published by Springer Nature in Cancer Imaging
- Vol. 25 (1) , 1-13
Open AccessLongitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE
Background: Accurate prediction of tumor response after drug-eluting beads transarterial chemoembolization (DEB-TACE) remains challenging in hepatocellular carcinoma (HCC), given tumor heterogeneity and dynamic changes over time. Existing prediction models based on single timepoint imaging do not capture dynamic treatment-induced changes. This study aims to develop and validate a predictive model that integrates deep learning and machine learning algorithms on longitudinal contrast-enhanced MRI (CE-MRI) to predict treatment response in HCC patients undergoing DEB-TACE. Methods: This retrospective study included 202 HCC patients treated with DEB-TACE from 2004 to 2023, divided into a training cohort ( n = 141) and validation cohort ( n = 61). Radiomics and deep learning features were extracted from standardized longitudinal CE-MRI to capture dynamic tumor changes. Feature selection involved correlation analysis, minimum redundancy maximum relevance, and least absolute shrinkage and selection operator regression. The patients were categorized into two groups: the objective response group ( n = 123, 60.9%; complete response = 35, 28.5%; partial response = 88, 71.5%) and the non-response group ( n = 79, 39.1%; stable disease = 62, 78.5%; progressive disease = 17, 21.5%). Predictive models were constructed using radiomics, deep learning, and integrated features. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of the models. Results: We retrospectively evaluated 202 patients (62.67 ± 9.25 years old) with HCC treated after DEB-TACE. A total of 7,182 radiomics features and 4,096 deep learning features were extracted from the longitudinal CE-MRI images. The integrated model was developed using 13 quantitative radiomics features and 4 deep learning features and demonstrated acceptable and robust performance with an receiver operating characteristic curve (AUC) of 0.941 (95%CI: 0.893–0.989) in the training cohort, and AUC of 0.925 (95%CI: 0.850–0.998) with accuracy of 86.9%, sensitivity of 83.7%, as well as specificity of 94.4% in the validation set. Conclusions: This study presents a predictive model based on longitudinal CE-MRI data to estimate tumor response to DEB-TACE in HCC patients. By capturing tumor dynamics and integrating radiomics features with deep learning features, the model has the potential to guide individualized treatment strategies and inform clinical decision-making regarding patient management.
- Open Access
- 1 August 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (4) , 676-679
Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial
Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial
- 1 August 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (4) , 676-679
Open AccessBeyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial
Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial
- Open Access
- 10 May 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (1) , 74-85
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
- 10 May 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (1) , 74-85
Open AccessSafety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial